Search Immortality Topics:

Page 3«..2345..1020..»


Category Archives: Biotechnology

Pharmaceutical and Biotechnology Environmental Monitoring Market: COVID 19 Proficient Analysis Shows Enormous Improvement in Revenue: Danaher…

Pharmaceutical and Biotechnology Environmental Monitoring Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2027. A Pharmaceutical and Biotechnology Environmental Monitoring market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

This Pharmaceutical and Biotechnology Environmental Monitoring market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

Download Sample PDF of Pharmaceutical and Biotechnology Environmental Monitoring Market Report https://www.worldwidemarketreports.com/sample/270219

Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Sinensis, Lonza, Biomerieux, VAI, Cosasco are some of the major organizations dominating the global market.

Key players in the Pharmaceutical and Biotechnology Environmental Monitoring market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Pharmaceutical and Biotechnology Environmental Monitoring market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

The report also makes some important suggestions for the new Pharmaceutical and Biotechnology Environmental Monitoring market project before evaluating its feasibility. Overall, this report covers Pharmaceutical and Biotechnology Environmental Monitoring market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

This report includes market size estimates of value (million US $) and volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Pharmaceutical and Biotechnology Environmental Monitoring market, estimating the size of various other submarkets in the overall market. Major players in the market were identified through secondary studies, and market share was determined through primary and secondary studies. All ratio sharing, splitting and analysis were determined using the secondary source and the identified primary source.

What Pharmaceutical and Biotechnology Environmental Monitoring Market report offers:

Regions Covered in This Report

Complete knowledge of the Pharmaceutical and Biotechnology Environmental Monitoring market is based on the latest industry news, opportunities and trends in the expected region. The Pharmaceutical and Biotechnology Environmental Monitoring market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Pharmaceutical and Biotechnology Environmental Monitoring Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

See the article here:
Pharmaceutical and Biotechnology Environmental Monitoring Market: COVID 19 Proficient Analysis Shows Enormous Improvement in Revenue: Danaher...

Posted in Biotechnology | Comments Off on Pharmaceutical and Biotechnology Environmental Monitoring Market: COVID 19 Proficient Analysis Shows Enormous Improvement in Revenue: Danaher…

Where Does Acer Therapeutics Inc (ACER) Stock Fall in the Biotechnology Field? – InvestorsObserver

Acer Therapeutics Inc (ACER) is around the middle of the Biotechnology industry according to InvestorsObserver. ACER received an overall rating of 49, which means that it scores higher than 49 percent of all stocks. Acer Therapeutics Inc also achieved a score of 36 in the Biotechnology industry, putting it above 36 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Acer Therapeutics Inc (ACER) stock is trading at $3.18 as of 11:42 AM on Monday, Jun 15, a decline of -$0.09, or -2.75% from the previous closing price of $3.27. The stock has traded between $3.02 and $3.27 so far today. Volume today is low. So far 53,121 shares have traded compared to average volume of 346,979 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original:
Where Does Acer Therapeutics Inc (ACER) Stock Fall in the Biotechnology Field? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Acer Therapeutics Inc (ACER) Stock Fall in the Biotechnology Field? – InvestorsObserver

Is Zymeworks Inc (ZYME) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

The 72 rating InvestorsObserver gives to Zymeworks Inc (ZYME) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 75 percent of stocks in the Biotechnology industry, ZYMEs 72 overall rating means the stock scores better than 72 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Zymeworks Inc (ZYME) stock is higher by 1.57% while the S&P 500 is down -1.97% as of 11:26 AM on Monday, Jun 15. ZYME is higher by $0.53 from the previous closing price of $34.15 on volume of 94,857 shares. Over the past year the S&P 500 is higher by 3.17% while ZYME is higher by 68.02%. ZYME lost -$3.88 per share the over the last 12 months.

To screen for more stocks like ZYME click here.

More here:
Is Zymeworks Inc (ZYME) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Zymeworks Inc (ZYME) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute – GlobeNewswire

FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institutes (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clinical trial involves a combination of PDS0101 with two clinical development-stage immune-modulating agents, Bintrafusp alfa (M7824) and NHS-IL12.

The NCI Center for Cancer Researchs Genitourinary Malignancies Branch (GMB) and Laboratory of Tumor Immunology and Biology (LTIB) are jointly leading this Phase 2 trial evaluating PDS0101, which combines the Versamune platform with targeted antigens in HPV-expressing cancers, in combination with Bintrafusp alfa (M7824) and NHS-IL12.

The trial will evaluate the objective response rate of this novel triple combination in approximately 35 patients with advanced HPV-associated cancers. The first eight patients will be evaluated for safety and objective response before the trial progresses to full enrollment.

We are excited to have the first patient dosed in this NCI-led Phase 2 clinical trial, which is an important next step in further demonstrating the power of our novel Versamune platform to induce high levels of tumor-specific CD8 killer T-cells, commented Dr. Lauren Wood, Chief Medical Officer of PDS Biotech. We believe that PDS0101s demonstrated preclinical efficacy when combined with these two immune-modulating agents, has the potential to significantly improve clinical outcomes for patients with advanced HPV-associated cancers.

Dr. Jeffrey Schlom, Chief, LTIB, and Dr. James Gulley, Chief, GMB, at NCI are serving as principal investigators for the NCI, while Dr. Frank Bedu-Addo and Dr. Lauren Wood, PDS Biotechs Chief Executive Officer and Chief Medical Officer respectively, will serve as PDS Biotechs investigators. The studies are being performed as part of a Cooperative Research and Development Agreement (CRADA) between PDS Biotech and the NCI.

Dr. Julius Strauss, Staff Clinician, LTIB, is serving as the principal investigator of this phase 2 clinical trial of PDS0101 in advanced HPV-associated cancers. For patients interested in enrolling in this clinical study, please call NCIs toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615), email NCIMO_Referrals@mail.nih.gov, and/or visit the website:https://trials.cancer.gov.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with standard of care chemoradiotherapy.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

See the original post:
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute - GlobeNewswire

Posted in Biotechnology | Comments Off on PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute – GlobeNewswire

Abbvie and Genmab team up in oncology – European Biotechnology News

AbbVie is partnering with Genmab A/Sto commercialise up to seven new antibody formats.

Under the licence agreement, AbbVie will pay Genmab US$750m upfront and up to US$3.15bn in potential milestones. In addition to co-developing three of Genmabs early-stage investigational bispecific DuoBody antibody product candidates (epcoritamab, DuoBody-CD3xCD20; DuoHexaBody-CD37 and DuoBody-CD3x5T4), the companies agreed to enter into a discovery research collaboration for developing future antibody therapeutics against cancer.

Under the discovery research collaboration, the new partners will combine Genmabs DuoBody technology and AbbVies ADC technology to develop up to four additional antibody conjugates, potentially across both solid tumours and blood cancers. Genmabs DuoBody-CD3 technology engages and directs cytotoxic T cells to selectively activate an immune response towards malignant cells. AbbVies ADC technology allows the selective delivery of a highly toxic compound directly to cancer cells that overexpress specific surface markers. The companies said this combined strategy may allow designing effective cancer therapies with fewer side effects.

For epcoritamab, companies will share commercial responsibilities in the U.S. and Japan, with AbbVie being responsible for the global commercialisation. Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales. For DuoHexaBody-CD37, DuoBody-CD3x5T4 and any product candidates resulting from the companies discovery research collaboration, Genmab and AbbVie will share responsibilities for global development and commercialization in the U.S. and Japan. Genmab retains the right to co-commercialize these products, along with AbbVie, outside of the U.S. and Japan. For the discovery research partnership, Genmab will conduct Phase 1 studies for these programmes. AbbVie retains the right to opt-in for programme development

Upon market approval of Genmabs product candidates, Abbvie will pay tiered royalties between 22% and 26% on net sales for epcoritamab outside the U.S. and Japan. Except for these royalty-bearing sales, the parties share in pre-tax profits from the sale of products on a 50-50 basis. These potential milestones are up to US$1.15bn in payments related to clinical development and commercial success across the three existing bispecific antibody programmes. Furthermore, if all four next-generation antibody product candidates developed as a result of the discovery research collaboration are successful, Genmab is eligible to receive up to US$2bn in option exercise and success-based milestone payments.

See original here:
Abbvie and Genmab team up in oncology - European Biotechnology News

Posted in Biotechnology | Comments Off on Abbvie and Genmab team up in oncology – European Biotechnology News

BGSBU gets 20 seats for department of Biotechnology from Union Ministry of Science and Technology – Greater Kashmir

In a significant development, the department of biotechnology in Union Ministry of Science and Technology, has sanctioned 20 seats to Baba Ghulam Shah Badshah University (BGSBU) Rajouri.

The intake had been sanctioned for M.sc biotechnology program under DBT-PG teaching program for the initial duration of five years.

This will carry a monthly stipend of Rs.5000 and dissertation grant of Rs 50,000 to each students in addition to other infrastructural support, an official at BGSBU said.

He said the admission to this program will be done through a centralized entrance test to be conducted by regional centre for Biotechnology, Faridabad.

Examination centres will be set up in Jammu and Srinagar division for the students who aspire to pursue the course, the official said.

The official said the details of centralized entrance test are available on http://www.rcb.res.in/GATB and also BGSBU website http://www.bgsbu.ac.in.

The last date for the online applications for this test has been fixed as June 18 and the test is scheduled to be held on June 30, 2020, the official said.

With the sanction of 20 seats for BGSBU, the candidates who have applied for M.Sc Biotechnology program of BGSBU will now be required to appear in the centralized entrance tests as well.

BGSBU will not conduct any entrance test for this program in view of new entrance test guidelines from DBT, he said.

Continued here:
BGSBU gets 20 seats for department of Biotechnology from Union Ministry of Science and Technology - Greater Kashmir

Posted in Biotechnology | Comments Off on BGSBU gets 20 seats for department of Biotechnology from Union Ministry of Science and Technology – Greater Kashmir